文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

高剂量利福平在结核- HIV共感染患者中的药代动力学、安全性与疗效研究方案

Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
PubMed 文献 · Trials · 2020-02-13

本研究为在乌干达坎帕拉开展的一项随机、开放标签、IIb期临床试验,纳入新诊断结核的HIV共感染成人门诊患者,比较标准剂量与高剂量利福平(35 mg/kg)联合标准抗结核治疗,并将未治或已治患者分配至DTG或EFV方案。主要评估高剂量利福平的安全性及其对EFV和DTG药代动力学的影响,每2周随访评估毒性,第6周测药物浓度,强化期8周后转为标准剂量继续期治疗。

要点

  • 高剂量利福平(35 mg/kg)在结核-HIV共感染患者中的安全性和药代动力学影响尚需前瞻性验证。
  • 正在接受DTG治疗的患者入组时需将DTG调整为每日两次给药。
  • 第6周进行药物浓度测定,每2周随访评估毒性直至强化期结束。

核心结论

  • 本研究旨在为高剂量利福平在结核-HIV共感染患者中对EFV和DTG药代动力学的影响及安全性提供证据。

研究设计与样本

  • 随机、开放标签、IIb期临床试验,在乌干达坎帕拉HIV门诊纳入新诊断结核的HIV共感染成人门诊患者。
  • 患者随机接受标准剂量或高剂量利福平(35 mg/kg)联合标准抗结核治疗。
  • 未治患者随机分配至DTG或EFV一线抗逆转录病毒方案;已治患者继续原方案但DTG调整为每日两次。

关键数值与推荐

  • 高剂量利福平剂量为35 mg/kg。
  • 每2周随访评估毒性,第6周测量药物浓度。
  • 强化期治疗8周后,所有参与者转为标准剂量利福平联合异烟肼的继续期治疗。

临床怎么用

  • 该方案可为结核-HIV共感染患者使用高剂量利福平及ART剂量调整提供临床决策依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB) is a significant public health problem that causes substantial morbidity and mortality. Current first-line anti-TB chemotherapy, although very effective, has limitations including long-treatment duration with a possibility of non-adherence, drug interactions, and toxicities. Dose escalation of rifampicin, an important drug within the regimen, has been proposed as a potential route to higher treatment efficacy with shorter duration and some studies have suggested that dose escalation is safe; however, these have almost entirely been conducted among human immunodeficiency (HIV)-negative TB patients. TB-HIV co-infected patients on antiretroviral therapy (ART) are at increased risk of drug-drug interactions and drug-related toxicities. This study aims to determine the safety of higher doses of rifampicin and its effect on the pharmacokinetics of efavirenz (EFV) and dolutegravir (DTG) in TB-HIV co-infected patients. METHODS: This study is a randomized, open-label, phase IIb clinical trial among TB-HIV infected adult outpatients attending an HIV clinic in Kampala, Uganda. Patients newly diagnosed with TB will be randomized to either standard-dose or high-dose rifampicin (35 mg/kg) alongside standard TB treatment. ART-naïve patients will be randomly assigned to first-line ART regimens (DTG or EFV). Those who are already on ART (DTG or EFV) at enrollment will be continued on the same ART regimen but with dose adjustment of DTG to twice daily dosing. Participants will be followed every 2 weeks with assessment for toxicities at each visit and measurement of drug concentrations at week 6. At the end of intensive-phase therapy (8 weeks), all participants will be initiated on continuation-phase treatment using standard-dose rifampicin and isoniazid. DISCUSSION: This study should avail us with evidence about the effect of higher doses of rifampicin on the pharmacokinetics of EFV and DTG among TB-HIV co-infected patients. The trial should also help us to understand safety concerns of high-dose rifampicin among this vulnerable cohort. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03982277. Registered retrospectively on 11 June 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nabisere R, Musaazi J, Denti P, et al. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials. 2020. PMID: 32054536. doi:10.1186/s13063-020-4132-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。